Characteristics and treatment of metaplastic breast cancer: Analysis of 892 cases from the national cancer data base

Christopher M. Pezzi, Lina Patel-Parekh, Karin Cole, Jan Franko, Vicki Klimberg, Kirby Bland

Research output: Contribution to journalArticle

143 Citations (Scopus)

Abstract

Background: Metaplastic breast cancer (MBC) is characterized by various combinations of adenocarcinoma, mesenchymal, and other epithelial components. It was officially recognized as a distinct pathologic diagnosis in 2000. With few published reports, we hypothesized that MBC may have markedly different characteristics at presentation than typical infiltrating ductal carcinoma (IDC) and may be managed differently. Methods: Data from patients with MBC and IDC reported to the National Cancer Database from January 2001 through December 2003 were reviewed for year of diagnosis, patient age, race/ethnicity, tumor size, nodal status, American Joint Committee on Cancer (AJCC) stage, tumor grade, hormone receptor status, and initial treatment, and were analyzed statistically by the Pearson χ2 test. Results: A total of 892 patients with MBC and 255,164 patients with IDC were identified. The group with MBC was older (mean age, 61.1 vs. 59.7 years; P = .001), had a significantly increased proportion of African American (14.1%, 126 of 892, vs. 10.2%, 25,900 of 255,164; odds ratio [OR], 1.455, P = .001) and Hispanic patients (5.5%, 49 of 892 vs. 3.9%, 9,947 of 255,164; OR, 1.817, P = .001), had fewer T1 tumors (29.5% vs. 65.2%), more N0 tumors (78.1% vs. 65.7%, OR, .5, P = .001), more poorly or undifferentiated tumors (67.8% vs. 38.8%), and fewer estrogen receptor-positive tumors (11.3% vs. 74.1%, OR, 22.4, P = .001) than the IDC group. Patients with MBC were treated with breast-conserving surgery less frequently than patients with IDC (38.5% vs. 55.8%, OR, 2.0, P = .001) because of the larger tumor size. Chemotherapy was used more often for patients with MBC (53.4% vs. 42.1%, OR, 1.6, P = .001) because of more advanced AJCC stage. Conclusions: MBC is a rare tumor with different characteristics than IDC: it presents with larger tumor size, less nodal involvement, higher tumor grade, and hormone receptor negativity. Patients with MBC are treated more aggressively than IDC (more often with mastectomy and chemotherapy) because of a higher stage at presentation, but are being treated by the same principles as IDC. Follow-up will determine the long-term results of the current treatment.

Original languageEnglish (US)
Pages (from-to)166-173
Number of pages8
JournalAnnals of Surgical Oncology
Volume14
Issue number1
DOIs
StatePublished - Jan 2007
Externally publishedYes

Fingerprint

Ductal Carcinoma
Databases
Breast Neoplasms
Neoplasms
Odds Ratio
Therapeutics
Hormones
Drug Therapy
Segmental Mastectomy
Mastectomy
Hispanic Americans
Estrogen Receptors
African Americans
Adenocarcinoma

Keywords

  • Breast cancer
  • Metaplastic

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Characteristics and treatment of metaplastic breast cancer : Analysis of 892 cases from the national cancer data base. / Pezzi, Christopher M.; Patel-Parekh, Lina; Cole, Karin; Franko, Jan; Klimberg, Vicki; Bland, Kirby.

In: Annals of Surgical Oncology, Vol. 14, No. 1, 01.2007, p. 166-173.

Research output: Contribution to journalArticle

Pezzi, Christopher M. ; Patel-Parekh, Lina ; Cole, Karin ; Franko, Jan ; Klimberg, Vicki ; Bland, Kirby. / Characteristics and treatment of metaplastic breast cancer : Analysis of 892 cases from the national cancer data base. In: Annals of Surgical Oncology. 2007 ; Vol. 14, No. 1. pp. 166-173.
@article{9be91732580340d5b0951e58b45c6235,
title = "Characteristics and treatment of metaplastic breast cancer: Analysis of 892 cases from the national cancer data base",
abstract = "Background: Metaplastic breast cancer (MBC) is characterized by various combinations of adenocarcinoma, mesenchymal, and other epithelial components. It was officially recognized as a distinct pathologic diagnosis in 2000. With few published reports, we hypothesized that MBC may have markedly different characteristics at presentation than typical infiltrating ductal carcinoma (IDC) and may be managed differently. Methods: Data from patients with MBC and IDC reported to the National Cancer Database from January 2001 through December 2003 were reviewed for year of diagnosis, patient age, race/ethnicity, tumor size, nodal status, American Joint Committee on Cancer (AJCC) stage, tumor grade, hormone receptor status, and initial treatment, and were analyzed statistically by the Pearson χ2 test. Results: A total of 892 patients with MBC and 255,164 patients with IDC were identified. The group with MBC was older (mean age, 61.1 vs. 59.7 years; P = .001), had a significantly increased proportion of African American (14.1{\%}, 126 of 892, vs. 10.2{\%}, 25,900 of 255,164; odds ratio [OR], 1.455, P = .001) and Hispanic patients (5.5{\%}, 49 of 892 vs. 3.9{\%}, 9,947 of 255,164; OR, 1.817, P = .001), had fewer T1 tumors (29.5{\%} vs. 65.2{\%}), more N0 tumors (78.1{\%} vs. 65.7{\%}, OR, .5, P = .001), more poorly or undifferentiated tumors (67.8{\%} vs. 38.8{\%}), and fewer estrogen receptor-positive tumors (11.3{\%} vs. 74.1{\%}, OR, 22.4, P = .001) than the IDC group. Patients with MBC were treated with breast-conserving surgery less frequently than patients with IDC (38.5{\%} vs. 55.8{\%}, OR, 2.0, P = .001) because of the larger tumor size. Chemotherapy was used more often for patients with MBC (53.4{\%} vs. 42.1{\%}, OR, 1.6, P = .001) because of more advanced AJCC stage. Conclusions: MBC is a rare tumor with different characteristics than IDC: it presents with larger tumor size, less nodal involvement, higher tumor grade, and hormone receptor negativity. Patients with MBC are treated more aggressively than IDC (more often with mastectomy and chemotherapy) because of a higher stage at presentation, but are being treated by the same principles as IDC. Follow-up will determine the long-term results of the current treatment.",
keywords = "Breast cancer, Metaplastic",
author = "Pezzi, {Christopher M.} and Lina Patel-Parekh and Karin Cole and Jan Franko and Vicki Klimberg and Kirby Bland",
year = "2007",
month = "1",
doi = "10.1245/s10434-006-9124-7",
language = "English (US)",
volume = "14",
pages = "166--173",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Characteristics and treatment of metaplastic breast cancer

T2 - Analysis of 892 cases from the national cancer data base

AU - Pezzi, Christopher M.

AU - Patel-Parekh, Lina

AU - Cole, Karin

AU - Franko, Jan

AU - Klimberg, Vicki

AU - Bland, Kirby

PY - 2007/1

Y1 - 2007/1

N2 - Background: Metaplastic breast cancer (MBC) is characterized by various combinations of adenocarcinoma, mesenchymal, and other epithelial components. It was officially recognized as a distinct pathologic diagnosis in 2000. With few published reports, we hypothesized that MBC may have markedly different characteristics at presentation than typical infiltrating ductal carcinoma (IDC) and may be managed differently. Methods: Data from patients with MBC and IDC reported to the National Cancer Database from January 2001 through December 2003 were reviewed for year of diagnosis, patient age, race/ethnicity, tumor size, nodal status, American Joint Committee on Cancer (AJCC) stage, tumor grade, hormone receptor status, and initial treatment, and were analyzed statistically by the Pearson χ2 test. Results: A total of 892 patients with MBC and 255,164 patients with IDC were identified. The group with MBC was older (mean age, 61.1 vs. 59.7 years; P = .001), had a significantly increased proportion of African American (14.1%, 126 of 892, vs. 10.2%, 25,900 of 255,164; odds ratio [OR], 1.455, P = .001) and Hispanic patients (5.5%, 49 of 892 vs. 3.9%, 9,947 of 255,164; OR, 1.817, P = .001), had fewer T1 tumors (29.5% vs. 65.2%), more N0 tumors (78.1% vs. 65.7%, OR, .5, P = .001), more poorly or undifferentiated tumors (67.8% vs. 38.8%), and fewer estrogen receptor-positive tumors (11.3% vs. 74.1%, OR, 22.4, P = .001) than the IDC group. Patients with MBC were treated with breast-conserving surgery less frequently than patients with IDC (38.5% vs. 55.8%, OR, 2.0, P = .001) because of the larger tumor size. Chemotherapy was used more often for patients with MBC (53.4% vs. 42.1%, OR, 1.6, P = .001) because of more advanced AJCC stage. Conclusions: MBC is a rare tumor with different characteristics than IDC: it presents with larger tumor size, less nodal involvement, higher tumor grade, and hormone receptor negativity. Patients with MBC are treated more aggressively than IDC (more often with mastectomy and chemotherapy) because of a higher stage at presentation, but are being treated by the same principles as IDC. Follow-up will determine the long-term results of the current treatment.

AB - Background: Metaplastic breast cancer (MBC) is characterized by various combinations of adenocarcinoma, mesenchymal, and other epithelial components. It was officially recognized as a distinct pathologic diagnosis in 2000. With few published reports, we hypothesized that MBC may have markedly different characteristics at presentation than typical infiltrating ductal carcinoma (IDC) and may be managed differently. Methods: Data from patients with MBC and IDC reported to the National Cancer Database from January 2001 through December 2003 were reviewed for year of diagnosis, patient age, race/ethnicity, tumor size, nodal status, American Joint Committee on Cancer (AJCC) stage, tumor grade, hormone receptor status, and initial treatment, and were analyzed statistically by the Pearson χ2 test. Results: A total of 892 patients with MBC and 255,164 patients with IDC were identified. The group with MBC was older (mean age, 61.1 vs. 59.7 years; P = .001), had a significantly increased proportion of African American (14.1%, 126 of 892, vs. 10.2%, 25,900 of 255,164; odds ratio [OR], 1.455, P = .001) and Hispanic patients (5.5%, 49 of 892 vs. 3.9%, 9,947 of 255,164; OR, 1.817, P = .001), had fewer T1 tumors (29.5% vs. 65.2%), more N0 tumors (78.1% vs. 65.7%, OR, .5, P = .001), more poorly or undifferentiated tumors (67.8% vs. 38.8%), and fewer estrogen receptor-positive tumors (11.3% vs. 74.1%, OR, 22.4, P = .001) than the IDC group. Patients with MBC were treated with breast-conserving surgery less frequently than patients with IDC (38.5% vs. 55.8%, OR, 2.0, P = .001) because of the larger tumor size. Chemotherapy was used more often for patients with MBC (53.4% vs. 42.1%, OR, 1.6, P = .001) because of more advanced AJCC stage. Conclusions: MBC is a rare tumor with different characteristics than IDC: it presents with larger tumor size, less nodal involvement, higher tumor grade, and hormone receptor negativity. Patients with MBC are treated more aggressively than IDC (more often with mastectomy and chemotherapy) because of a higher stage at presentation, but are being treated by the same principles as IDC. Follow-up will determine the long-term results of the current treatment.

KW - Breast cancer

KW - Metaplastic

UR - http://www.scopus.com/inward/record.url?scp=33845599160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845599160&partnerID=8YFLogxK

U2 - 10.1245/s10434-006-9124-7

DO - 10.1245/s10434-006-9124-7

M3 - Article

C2 - 17066230

AN - SCOPUS:33845599160

VL - 14

SP - 166

EP - 173

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 1

ER -